This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NuGenerex Immuno-Oncology Valuation

Is NUGX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NUGX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NUGX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NUGX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NUGX?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for NUGX. This is calculated by dividing NUGX's market cap by their current preferred multiple.
What is NUGX's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$10.12k

NUGX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does NUGX's PB Ratio compare to its peers?

The above table shows the PB ratio for NUGX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	0.00001x
GDBY.F Goodbody Health	n/a	n/a	US$36.0
GNRS Greenrose Holding	n/a	n/a	US$1.8k
SUWN Sunwin Stevia International	n/a	n/a	US$59.9k
INLB Item 9 Labs	0.00001x	n/a	US$701.0
NUGX NuGenerex Immuno-Oncology	n/a	n/a	US$10.1k

Price-To-Book vs Peers: Insufficient data to calculate NUGX's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Earnings Ratio vs Industry

How does NUGX's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	23.6%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	23.6%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: Insufficient data to calculate NUGX's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is NUGX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NUGX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	n/a
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NUGX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.